Rilzabrutinib has demonstrated sustained platelet responses and improved symptoms in patients with immune thrombocytopenia (ITP) according to long-term extension data from the LUNA 3 trial. Presented...
A recent clinical trial has demonstrated that the investigational drug ianalumab, when combined with standard therapy, significantly extends the time to treatment failure for patients suffering...
Patients with immune thrombocytopenia (ITP) who received the investigational drug ianalumab alongside standard therapy experienced significantly longer periods without treatment failure compared to those given a...
A recent study indicates that a virtual program targeting diet and exercise may effectively reduce the side effects of lymphoma treatment while enhancing patient adherence to...
Research presented at the American Society of Hematology (ASH) annual meeting in Orlando indicates that stem cell transplants using mismatched unrelated donors (MMUDs) with less than...
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody therapy, designated 77A, which has demonstrated potential in enhancing immune responses...
Treatment with a novel antibody therapy has shown the potential to eliminate residual traces of multiple myeloma, a type of blood cancer, according to interim results...
The annual meeting of the American Society of Hematology (ASH) is set to commence in Orlando this week, drawing significant attention from healthcare professionals and researchers...
The annual meeting of the American Society of Hematology (ASH) is set to take place in Orlando, with significant attention on the presentation by the Food...
The American Society of Hematology (ASH) annual meeting is set to take place in Orlando, attracting attention from healthcare professionals, researchers, and industry leaders. This prominent...
